Merck and Schering-Plough to Merge
- Details
- Category: Merck
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough.
Roche increases offer price for Genentech shares to US$ 93 per share
- Details
- Category: Roche
Roche (SWX: ROG.VX; RO.S) has increased its offer price for all outstanding publicly-held shares of Genentech (NYSE: DNA) to US$ 93 per share and extended the offer to 12:00 midnight, New York City time, on Friday, March 20, 2009. All other terms and conditions of the tender offer remain unchanged.
Lundbeck meets all of its financial forecasts for 2008 and expects continuing growth in 2009
- Details
- Category: Lundbeck
Lundbeck has presented annual accounts in which all of the financial results meet the financial guidance announced by the company in March 2008. For the first time ever, revenue exceeded DKK 11 billion in 2008, and Lundbeck's management considers the results highly satisfactory.
New diagnostic tool for Hypoactive Sexual Desire Disorder (HSDD) in women
- Details
- Category: Boehringer Ingelheim
Results from a study published today in the Journal of Sexual Medicine show that a new, easy to use five-question diagnostic tool can significantly reduce the time it takes to diagnose the most common form of female sexual dysfunction (FSD), generalised, acquired Hypoactive Sexual Desire Disorder* (HSDD).
Pfizer Expands Portfolio of Generic Medicines in the U.S. and Europe
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) announced today that it has entered into a series of agreements with Aurobindo Pharma Ltd., a pharmaceutical company based in India, to commercialize medicines that are no longer patent protected, and have lost market exclusivity in the United States and Europe, further progressing its Established Products Business Unit strategy.
AstraZeneca and MAP Pharmaceuticals, Inc. Announce Worldwide Collaboration
- Details
- Category: AstraZeneca
AstraZeneca and MAP Pharmaceuticals, Inc. have announced an exclusive worldwide agreement to develop and commercialise Unit Dose Budesonide (UDB), MAP Pharmaceuticals' proprietary nebulised formulation of budesonide. UDB is being developed by MAP Pharmaceuticals as a potential treatment for paediatric asthma and is currently in Phase III clinical development.
Advances in Renal Cancer Journalists' Award
- Details
- Category: Bayer
Bayer HealthCare and the Association of German Medical Journalists (VDMJ) have jointly announced the 2009 Advances in Renal Cancer Journalistsâ Award Europe, which will honor journalists who have dealt with the issue of renal cancer in a critical and objective manner. The award, endowed with EUR 7,500, is donated by Bayer HealthCare. Eligible for the award are printed media, radio, television and film reports.
More Pharma News ...
- Novartis shareholders approved 25% dividend increase
- Abbott Successfully Completes Tender Offer for Shares of Advanced Medical Optics
- Pfizer Discontinues Development of Two Phase 3 Compounds
- Nycomed reports a satisfactory 2008
- Schering-Plough announces collaboration with World Health Organization
- Encouraging results support further development of Almirall's long-acting beta-agonist (LABA)
- Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics